Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy progress and prospects: the eye.

J W B Bainbridge1, M H Tan, R R Ali

  • 1Division of Molecular Therapy, Institute of Ophthalmology, University College London, London, UK.

Gene Therapy
|July 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growing dune encroachment threatens the habitability of the western Nile riverbank.

Scientific reports·2026
Same author

Exogenous bone sialoprotein improves extraction socket healing in Ibsp knockout and wild-type mice.

Bone·2024
Same author

Retraction Note: Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations.

Gene therapy·2024
Same author

[Exophytic teratoma-like parasitic fetus in the sacrococcygeal region of the fetus: report of a case].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2024
Same author

Correction: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.

Gene therapy·2024
Same author

Author Correction: Restoration of vision after transplantation of photoreceptors.

Nature·2024
Same journal

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Gene therapy·2026
Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026
Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026
Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026
Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026
Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026
See all related articles

Gene therapy shows promise for inherited and acquired eye diseases, utilizing the eye

Area of Science:

  • Ophthalmology and Genetics
  • Gene Therapy and Ocular Disorders

Background:

  • The eye presents unique advantages as a target for gene therapy due to its accessibility for examination and in vivo assessment.
  • Inherited retinal degenerations caused by specific gene defects are being targeted with gene replacement therapies.

Purpose of the Study:

  • To explore the potential of gene therapy for inherited and acquired ocular disorders.
  • To highlight the eye as a model system for gene therapy research and development.

Main Methods:

  • Development of gene replacement therapies using recombinant adeno-associated virus and lentivirus vectors.
  • Targeted sustained intraocular delivery of therapeutic proteins for acquired disorders.
  • Phenotypic examination and in vivo investigation using fundus imaging and electrophysiological techniques.

Related Experiment Videos

Main Results:

  • Significant progress in gene replacement therapies for photoreceptor and retinal pigment epithelial cell defects.
  • Gene therapy offers a potential treatment for complex acquired ocular conditions involving angiogenesis, inflammation, and degeneration.

Conclusions:

  • Gene therapy is a promising approach for treating a range of ocular disorders, both inherited and acquired.
  • Ethical approval has been granted for clinical trials targeting early-onset retinal degeneration due to RPE65 gene defects.